Sophiris Bio (NASDAQ:SPHS) Receiving Somewhat Favorable News Coverage, Report Shows

Media headlines about Sophiris Bio (NASDAQ:SPHS) have been trending somewhat positive on Sunday, according to Accern. Accern ranks the sentiment of media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Sophiris Bio earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 45.0704159025933 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Several equities research analysts recently commented on the stock. Maxim Group reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Sophiris Bio in a research report on Wednesday, June 20th. HC Wainwright set a $6.00 price target on shares of Sophiris Bio and gave the company a “buy” rating in a research note on Tuesday, May 15th. Finally, ValuEngine upgraded shares of Sophiris Bio from a “sell” rating to a “hold” rating in a research note on Tuesday, May 1st.

Sophiris Bio traded up $0.02, reaching $2.75, during trading on Friday, according to MarketBeat Ratings. The company’s stock had a trading volume of 58,682 shares, compared to its average volume of 193,367. The company has a debt-to-equity ratio of 1.30, a current ratio of 5.90 and a quick ratio of 5.90. Sophiris Bio has a 12 month low of $1.80 and a 12 month high of $4.05.

Sophiris Bio (NASDAQ:SPHS) last posted its quarterly earnings data on Monday, May 14th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.13) by $0.02. research analysts predict that Sophiris Bio will post -0.51 EPS for the current year.

About Sophiris Bio

Sophiris Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302, which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer.

Featured Story: Closed-End Mutual Funds (CEFs)

Insider Buying and Selling by Quarter for Sophiris Bio (NASDAQ:SPHS)

Receive News & Ratings for Sophiris Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio and related companies with's FREE daily email newsletter.

Leave a Reply